What's the next innovation in Oncology?

Investment in Oncology is strong but dynamic: In 2016, major deals facilitated big moves in the Hot Indications list. One focus was immuno-oncology combinations, which have driven collaboration between big pharma and biotech.

This Deep Dive includes:
  • Update on the top indications within Oncology
  • Analysis of the biggest movers and losers within Oncology
  • Insights on acquisitions, drug approvals, and pipeline activity

Complete the form to download our Oncology Deep Dive. 

 

Have you seen our full list of 2016 Hot Indications? Click here to see this year's list.